The international clinical trial, co-led by OCI Clinician Scientist Amit Oza, examined 1,528 women with ovarian cancer over a period of seven years. Avastin® was administered intravenously every three weeks for a period of 12 months and results demonstrated that its administration held off disease recurrence for two months. For women with the highest disease risk, the delay was five to six months. The findings also indicate a strong trend to improved overall survival, which is currently undergoing investigation in a clinical trial ending in 2013.

“This is the first new drug for ovarian cancer in 15 years to show improved outcome and I believe it should be considered as a potential new standard of care,” says Dr. Oza.

«Back